Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy

CW Elgarten, R Aplenc - Current Opinion in Pediatrics, 2020 - journals.lww.com
Further incorporation of genomic and molecular data in pediatric AML will allow for
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …
被引用次数：110 相关文章
[PDF] thd.org.tr

[PDF][PDF] CURRENT OPINION Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy

CW Elgartena, R Aplenca - Curr Opin Pediatr, 2020 - thd.org.tr
Further incorporation of genomic and molecular data in pediatric AML will allow for
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …

Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy.

CW Elgarten, R Aplenc - Current Opinion in Pediatrics, 2020 - europepmc.org
Further incorporation of genomic and molecular data in pediatric AML will allow for
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …

Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy

CW Elgarten, R Aplenc - Current opinion in pediatrics, 2020 - pubmed.ncbi.nlm.nih.gov
Purpose of review Despite advances in therapy over the past decades, overall survival for
children with acute myeloid leukemia (AML) has not exceeded 70%. In this review, we …
[PDF] thd.org.tr

[PDF][PDF] CURRENT OPINION Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy

CW Elgartena, R Aplenca - Curr Opin Pediatr, 2019 - thd.org.tr
Further incorporation of genomic and molecular data in pediatric AML will allow for
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …